Reaction

Osteochondrosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,155 reports · 30 co-occurring drugs

As of the last recalculation, Osteochondrosis appears in 1,155 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is TORSEMIDE (PRR 32.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Torsemide	56	32.0	32.0
Captopril	16	30.4	30.4
Valsartan Oral	79	28.1	28.1
Somatropin	104	27.9	28.0
Febuxostat Tablets 40 Mg	13	23.3	23.3
Febuxostat Tablets 80 Mg	13	23.3	23.3
Nebivolol	20	23.0	23.0
Baricitinib	12	22.7	22.7
Felodipine Extended-Release Tablets	13	20.8	20.8
Felodipine	13	20.8	20.8
Candesartan	37	19.3	19.3
Granisetron Hydrochloride	11	19.2	19.2
Granisetron	11	19.1	19.1
Tenofovir Disoproxil Fumarate Tablets	8	16.8	16.8
Dalteparin Sodium	9	15.4	15.5
Valsartan	80	14.7	14.7
Febuxostat	13	14.1	14.1
Pertuzumab	19	12.8	12.8
Tofacitinib Citrate	9	12.5	12.5
Emtricitabine And Tenofovir Alafenamide	7	11.2	11.2
Nebivolol Hydrochloride	20	10.8	10.9
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	5	10.0	10.1
Pazopanib Hydrochloride	14	9.4	9.4
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	5	9.0	9.0
Tenofovir Disoproxil Fumarate	14	7.7	7.7
Docetaxel Anhydrous	24	6.5	6.5
Docetaxel	24	6.5	6.5
Emtricitabine And Tenofovir Disoproxil Fumarate	14	5.6	5.6
Abiraterone	4	5.3	5.3
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	5	5.0	5.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.